Ranpak Expands Automation, Packaging Partnership With Medline

Medline Inc. :  Barclays Initiates Coverage With Overweight Rating and Target Price $50

Medline Inc. : Citigroup Initiates Coverage With Buy Rating; Target Price $48

Medline (MDLN.US) Momentum Continues as Wall Street Unites in Praise, Market Cap Surges Past $57 Billion in 2025's Largest IPO

Medline Poised to Leverage Business Model to Outsized Performance, RBC Says

Medline Poised to Sustain High-Single Digit Organic Growth, BofA Says

BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners

Medline Stock (MDLN) Surges on a Wave of Post-IPO Buy Notes from Analysts

Medline Inc. : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $50

Medline initiated with an Outperform at Wolfe Research

Medline Inc. : William Blair Initiates Coverage With Outperform Rating

Medline Inc. : Mizuho Initiates Coverage With Outperform Rating; Target Price $48

Medline initiated with an Equal Weight at Wells Fargo

Medline Inc. : Stifel Initiates Coverage With Buy Rating; Target Price $46

Medline Inc. : Bernstein Initiates Coverage With Outperform Rating; Price Target $49

RBC Initiates Medline at Outperform With $47 Price Target

Medline: Durable Moat, Secular Tailwinds, and Attractive Valuation Support Buy Rating

Medline: Durable Growth, Expanding Market Share, and Margin Upside Support Buy Rating and $46 Target

Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward